Cleerly LABS vs Cleerly ISCHEMIA

Both Cleerly LABS and Cleerly ISCHEMIA are described as web-based platforms utilizing the Cleerly Proxy for data transfer, suggesting a similar underlying architecture and user interface. While LABS mentions broader integration with PACS, RIS, and EHR, ISCHEMIA highlights interactive web-based reports and PowerScribe integration. Without specific UI/UX details, it's difficult to definitively distinguish their usability.

Cleerly LABS offers a more comprehensive analysis, encompassing plaque assessment, stenosis detection, personalized risk assessment, and the ability to track disease progression over time. Crucially, it explicitly states 'Ischemia detection (with Cleerly ISCHEMIA module)', implying it either integrates or includes the core functionality of Tool B. This broader scope provides a more complete clinical picture for personalized heart disease management.

Cleerly LABS provides transparent pricing, stating a retail price and a current discounted rate per analysis, which allows users to understand the cost upfront. In contrast, Cleerly ISCHEMIA's pricing is opaque, requiring direct contact for details and stating it 'Varies by provider.' This lack of transparency makes it harder to assess its value proposition compared to Tool A.

Both tools are from the same vendor, utilize a similar cloud-based deployment model (AWS for LABS) with the Cleerly Proxy for secure data transfer, and share the same regulatory clearances including FDA, HIPAA compliance, and BAA availability. Their respective integrations (PACS/RIS/EHR for LABS, PowerScribe for ISCHEMIA) demonstrate a comparable level of readiness for integration into existing healthcare enterprise workflows.

While both tools leverage AI for CCTA analysis, Cleerly ISCHEMIA's specific capability for non-invasive fractional flow reserve (FFR) estimation represents a significant innovation. This feature offers a less invasive alternative to traditional FFR measurements, potentially streamlining diagnostic pathways and reducing patient risk. LABS is comprehensive, but ISCHEMIA's FFR estimation is a more targeted and potentially disruptive advancement.

The provided structured facts do not contain any specific information regarding support or documentation for either Cleerly LABS or Cleerly ISCHEMIA. As both products are developed by the same company, Cleerly, it is reasonable to assume they would share a common support infrastructure and documentation standards. Without further details, a distinction cannot be made.